Pharmacotherapy for multiple sclerosis: Progress and prospects

Current Opinion in Investigational Drugs

Volumn 10, Issue 5, 2009, Pages 407-417

  Palmer, A M ^a  

^a MS Therapeutics Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 874; ALEMTUZUMAB; ATACICEPT; ATL 1102; AVE 9897; BETA INTERFERON; BETA1A INTERFERON; BG 00012; BHT 3009; CDP 323; CLADRIBINE; DACLIZUMAB; FINGOLIMOD; FIRATEGRAST; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; INTEGRIN; INTERFERON BETA SERINE; LAQUINIMOD; MITOXANTRONE; MLN 3897; MYELIN BASIC PROTEIN[82-98]; NATALIZUMAB; OCRELIZUMAB; RITUXIMAB; SODIUM CHANNEL BLOCKING AGENT; SOLOVAX; TERIFLUNOMIDE; TRIMESTA; UNCLASSIFIED DRUG;

ALOPECIA; ARTHRALGIA; BIOLOGICAL THERAPY; BLADDER INFECTION; BLOOD BRAIN BARRIER; BONE MARROW SUPPRESSION; CELL ADHESION; CLINICAL TRIAL; DEPRESSION; DISEASE COURSE; DISEASE EXACERBATION; FATIGUE; FLU LIKE SYNDROME; HEADACHE; HEART INJURY; HUMAN; IMMUNOTHERAPY; INFECTION; LIPOATROPHY; LIVER INJURY; LOWER RESPIRATORY TRACT INFECTION; MUCOSA INFLAMMATION; MULTIPLE SCLEROSIS; NAUSEA; NEUROLOGIC DISEASE; ORAL MUCOSAL DISEASE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; THORAX PAIN; URINARY TRACT INFECTION;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; MULTIPLE SCLEROSIS;

EID: 67649363909     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (112)

1. Compston A, Coles A: Multiple sclerosis. Lancet (2008) 372(9648):1502-1517.
2. Compston A, Skupinski E, Noseworthy J, Lassmann H, Miller D, Rayner R, Smith K, Wekerle H, Confavreux C (Eds): McAlpine's Multiple Sclerosis. Elsevier, London, UK (2005).
3. Carswell R (Ed): Pathological Anatomy: Illustrations of the Elementary Forms of Disease. Longman, Orme, Brown, Green and Longman, London, UK (1838).
4. Pearce JM: Historical descriptions of multiple sclerosis. Eur Neurol (2005) 54(1):49-53.
5. Atlas: Multiple sclerosis resources in the world 2008. Multiple Sclerosis International Federation, London, UK (2008). www.msif.org/document. rm?id=476.
6. Who gets MS? The National MS Society, New York, NY, USA (2009). www.nationalmssociety.org/about-multiple-sclerosis/who-gets-ms/index. aspx.
7. Jones CA, Pohar SL, Warren S, Turpin KV, Warren KG: The burden of multiple sclerosis: A community health survey. Health Qual Life Outcomes (2008) 6:1.
8. Alonso A, Hermán MA: Temporal trends in the incidence of multiple sclerosis: A systematic review. Neurology (2008) 71(2):129-135.
9. Zivadinov R, Iona L, Monti-Bragadin L, Bosco A, Jurjevic A, Taus C, Cazzato G, Zorzon M: The use of standardized incidence and prevalence rates in epidemiological studies on multiple sclerosis. A meta-analysis study. Neuroepidemiology (2003) 22(1):65-74.
10. Kurtzke JF: Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology (1983) 33(11):1444-1452.
11. D'Souza M, Kappos L, Czaplinski A: Reconsidering clinical outcomes in multiple sclerosis: Relapses, impairment, disability and beyond. J Neurol Sci (2008) 274(1-2):76-79.
12. Goodkin DE, Cookfair D, Wende K, Bourdette D, Pullicino P, Scherokman B, Whitham R: Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Multiple Sclerosis Collaborative Research Group. Neurology (1992) 42(4):859-863.
13. Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, Syndulko K, Weinshenker BG, Antel JP, Confavreux C, Ellison GW et al: Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain (1999) 122(Pt 5): 871-882.
14. Balcer LJ: Clinical outcome measures for research in multiple sclerosis. J Neuroophthalmol (2001) 21(4):296-301.
15. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg- Wollheim M et al: Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol (2001) 50(1):121-127.
16. Paty DW, Oger JJ, Kastrukoff LF, Hashimoto SA, Hooge JP, Eisen AA, Eisen KA, Purves SJ, Low MD, Brandejs V et al: MRI in the diagnosis of MS: A prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology (1988) 38(2):180-185.
17. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M et al: Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol (2005) 58(6):840- 846.
18. Bakshi R, Neema M, Healy BC, Liptak Z, Betensky RA, Buckle GJ, Gauthier SA, Stankiewicz J, Meier D, Egorova S, Arora A et al: Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale. Arch Neurol (2008) 65(11):1449-1453.
19. Furby J, Hayton T, Anderson V, Altmann D, Brenner R, Chataway J, Hughes R, Smith K, Miller D, Kapoor R: Magnetic resonance imaging measures of brain and spinal cord atrophy correlate with clinical impairment in secondary progressive multiple sclerosis. Mult Scler (2008) 14(8):1068-1075.
20. Bar-Zohar D, Agosta F, Goldstaub D, Filippi M: Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: A review of the literature and future perspectives. Mult Scler (2008) 14(6):719-727.
21. Sánchez MP, Nieto A, Barroso J, Martin V, Hernandez MA: Brain atrophy as a marker of cognitive impairment in mildly disabling relapsing-remitting multiple sclerosis. Eur J Neurol (2008) 15(10):1091-1099.
22. Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, Freedman MS, Galetta SL, Hutchinson M, Johnson RT, Kappos L, Kira J et al: Differential diagnosis of suspected multiple sclerosis: A consensus approach. Mult Scler (2008) 14(9):1157-1174.
23. Pandey K, Lublin FD: Clinically isolated syndrome and multiple sclerosis: Rethinking the arsenal. Curr Treat Options Neurol (2009) 11(3):193-202.
24. Santos EC, Yokota M, Dias NF: Multiple sclerosis: Study of patients with relapsing-remitting form registered at Minas Gerais Secretary of State for Health. Arq Neuropsiquiatr (2007) 65(3B):885-888.
25. Fisniku LK, Brex PA, Altmann DR, Miszkiel KA, Benton CE, Lanyon R, Thompson AJ, Miller DH: Disability and T2 MRI lesions: A 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain (2008) 131(3):808-817.
26. Miller DH, Leary SM: Primary-progressive multiple sclerosis. Lancet Neurol (2007) 6(10):903-912
27. Confavreux C, Vukusic S: Age at disability milestones in multiple sclerosis. Brain (2006) 129(Pt 3):595-605.
28. Confavreux C, Vukusic S: Natural history of multiple sclerosis: A unifying concept. Brain (2006) 129(Pt 3):606-616.
29. McElroy JP, Oksenberg JR: Multiple sclerosis genetics. Curr Top Microbiol Immunol (2008) 318:45-72.
30. Ebers GC: Environmental factors and multiple sclerosis. Lancet Neurol (2008) 7(3):268-277.
31. Ascherio A, Munger KL: Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol (2007) 61(6):504-513.
32. Ascherio A, Munger KL: Environmental risk factors for multiple sclerosis. Part I: The role of infection. Ann Neurol (2007) 61(4):288-299.
33. Pugliatti M, Harbo HF, Holmpy T, Kampman MT, Myhr KM, Riise T, Wolfson C: Environmental risk factors in multiple sclerosis. Acta Neurol Scand Suppl (2008) 188:34-40.
34. Pender MP, Csurhes PA, Lenarczyk A, Pfluger CM, Burrows SR: Decreased T cell reactivity to Epstein-Barr virus infected lymphoblastoid cell lines in multiple sclerosis. J Neurol Neurosurg Psychiatry (2009) 80(5):498-505.
35. Engelhardt B: The blood-central nervous system barriers actively control immune cell entry into the central nervous system. CurrPharm Des (2008) 14(16):1555-1565.
36. Engelhardt B: Immune cell entry into the central nervous system: Involvement of adhesion molecules and chemokines. J Neurol Sci (2008) 274(1-2):23-26.
37. Sheremata WA, Minagar A, Alexander JS, Vollmer T: The role of α-4 integrin in the aetiology of multiple sclerosis: Current knowledge and therapeutic implications. CNS Drugs (2005) 19(11):909-922.
38. Neumann H, Medana IM, Bauer J, Lassmann H: Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci (2002) 25(6):313-319.
39. Anderton SM, Liblau RS: Regulatory T cells in the control of inflammatory demyelinating diseases of the central nervous system. Curr Opin Neurol (2008) 21(3):248-254.
40. McFarland HF, Martin R: Multiple sclerosis: A complicated picture of autoimmunity. Nat Immunol (2007) 8(9):913-919.
41. Smith KJ: Sodium channels and multiple sclerosis: Roles in symptom production, damage and therapy. Brain Pathol (2007) 17(2):230-242.
42. Waxman SG: Mechanisms of disease: Sodium channels and neuroprotection in multiple sclerosis - Current status. Nat Clin Pract Neurol (2008) 4(3):159-169.
43. Schouten JW: Neuroprotection in traumatic brain injury: A complex struggle against the biology of nature. Curr Opin Crit Care (2007) 13(2):134-142.
44. Weinstock-Guttman B, Ramanathan M, Zivadinov R: Interferon-β treatment for relapsing multiple sclerosis. Expert Opin Biol Ther (2008) 8(9):1435-1447.
45. Rice GP, Incorvaia B, Munari L, Ebers G, Polman C, D'Amico R, Filippini G: Interferon in relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev (2001):CD002002.
46. Munari L, Lovati R, Boiko A: Therapy with glatiramer acetate for multiple sclerosis. Cochrane Database Syst Rev (2004):CD004678.
47. Clerico M, Faggiano F, Palace J, Rice G, Tintore M, Durelli L: Recombinant interferon β or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. Cochrane Database Syst Rev (2008):CD005278.
48. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalban X, Barkhof F, Radü EW, Bauer L, Dahms S et al: Effect of early versus delayed interferon β-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: A 3-year follow-up analysis of the BENEFIT study. Lancet (2007) 370(9585):389- 397.
49. Fox EJ: Management of worsening multiple sclerosis with mitoxantrone: A review. Clin Ther (2006) 28(4):461-474.
50. Martinelli BF, Rovaris M, Capra R, Comi G: Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev (2005):CD002127.
51. Engelhardt B, Kappos L: Natalizumab: Targeting α-integrins in multiple sclerosis. Neurodegener Dis (2008) 5(1):16-22.
52. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M et al: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med (2006) 354(9):899-910.
53. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA et al: Natalizumab plus interferon β-1a for relapsing multiple sclerosis. N Engl J Med (2006) 354(9):911-923.
54. Berger JR: Progressive multifocal leukoencephalopathy. Curr Neurol Neurosci Rep (2007) 7(6):461-469.
55. 4-Integrin antagonism with natalizumab: Effects and adverse effects. J Neurol (2008) 255(Suppl 6):58-65.
56. 4-integrin antagonism - an effective approach for the treatment of inflammatory diseases? Drug Discov Today (2007) 12(13-14):569-576.
57. Kieseier BC, Wiendl H, Hemmer B, Hartung HP: Treatment and treatment trials in multiple sclerosis. Curr Opin Neurol (2007) 20(3):286-293.
58. Kieseier BC, Wiendl H: Oral disease-modifying treatments for multiple sclerosis: The story so far. CNS Drugs (2007) 21(6):483-502.
59. Menge T, Weber MS, Hemmer B, Kieseier BC, von Büdingen HC, Warnke C, Zamvil SS, Boster A, Khan O, Hartung HP, Stüve O: Disease- modifying agents for multiple sclerosis: Recent advances and future prospects. Drugs (2008) 68(17):2445-2468.
60. Stüve O, Bennett JL, Hemmer B, Wiendl H, Racke MK, Bar-Or A, Hu W, Zivadinov R, Weber MS, Zamvil SS, Pacheco MF et al: Pharmacological treatment of early multiple sclerosis. Drugs (2008) 68(1):73-83.
61. Linker RA, Kieseier BC, Gold R: Identification and development of new therapeutics for multiple sclerosis. Trends Pharmacol Sci (2008) 29(11):558-565.
62. Gasperini C, Cefaro LA, Borriello G, Tosto G, Prosperini L, Pozzilli C: Emerging oral drugs for multiple sclerosis. Expert Opin Emerg Drugs (2008) 13(3):465-477.
63. Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK: Alemtuzumab vs. interferon β-1a in early multiple sclerosis. N Engl J Med (2008) 359(17):1786-1801.
64. Drug datasheet: Campath (alemtuzumab). Berlex Laboratories, Montville, NJ, USA (2002). berlex.bayerhealthcare.com/html/ products/pi/Campath-PI.pdf
65. Bar-Or A, Calabresi PA, Arnold D, Markowitz C, Shafer S, Kasper LH, Waubant E, Gazda S, Fox RJ, Panzara M, Sarkar N et al: Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial. Ann Neurol (2008) 63(3):395-400.
66. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A et al: B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med (2008) 358(7):676-688.
67. Rose JW, Burns JB, Bjorklund J, Klein J, Watt HE, Carlson NG: Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology (2007) 69(8): 785-789.
68. Bielekova B, Howard T, Packer AN, Richert N, Blevins G, Ohayon J, Waldmann TA, McFarland HF, Martin R: Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 2009 66(4):483-489.
69. European Agency for the Evaluation of Medicinal Products: Public statement on Zenapax (daclizumab) withdrawal of the marketing authorisation in the European Union. Press Release (2009): 23 January.
70. O'Connor P, Comi G, Montalban X, Antel J, Radue EW, de Vera A, Pohlmann H, Kappos L, FTY720 D2201 Study Group: Oral fingolimod (FTY720) in multiple sclerosis: Two-year results of a phase II extension study. Neurology (2000) 72(1):73-79.
71. Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, Gold R, Havrdova E, Komoly S, Selmaj K, Sharrack B et al: Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: A multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet (2008) 371(9630):2085-2092.
72. Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T: Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology (2005) 64(6):987-991.
73. Teva Pharmaceutical Industries Ltd: Oral laquinimod for multiple sclerosis granted Fast Track status by FDA. Press Release (2009): 12 February.
74. Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, Eraksoy M et al: Efficacy and safety of oral fumarate in patients with relapsing- remitting multiple sclerosis: A multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet (2008) 372(9648):1463-1472.
75. Linker RA, Lee DH, Stangel M, Gold R: Fumarates for the treatment of multiple sclerosis: Potential mechanisms of action and clinical studies. Expert Rev Neurother (2008) 8(11):1683-1690.
76. O'Connor PW, Li D, Freedman MS, Bar-Or A, Rice GP, Confavreux C, Paty DW, Stewart JA, Scheyer R: A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology (2006) 66(6):894-900.
77. Tallantyre E, Evangelou N, Constantinescu CS: Spotlight on teriflunomide. Int MS J (2008) 15(2):62-68.
78. Martinez-Rodriguez JE, Cadavid D, Wolansky LJ, Pliner L, Cook SD: Cladribine in aggressive forms of multiple sclerosis. Eur J Neurol (2007) 14(6):686-689.
79. Brousil JA, Roberts RJ, Schlein AL: Cladribine: An investigational immunomodulatory agent for multiple sclerosis. Ann Pharmacother (2006) 40(10):1814-1821.
80. Rice GP, Filippi M, Comi G: Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology (2000) 54(5):1145-1155.
81. Leist TP, Vermersch P: The potential role for cladribine in the treatment of multiple sclerosis: Clinical experience and development of an oral tablet formulation. Curr Med Res Opin (2007) 23(11):2667-2676.
82. Giovannoni G, Comi G, Cook S, Beelke M, Rieckmann P, Sprensen PS, Vermersch P: The CLARITY study (CLAdRIbine tablets Treating multiple sclerosis orallY): Design of a phase III trial of oral cladribine in relapsing multiple sclerosis. Mult Scler (2007) 13(Suppl 2):S7-S273, P808.
83. Tortorella C, Rovaris M, Filippi M: Cladribine. Ortho Biotech Inc. Curr Opin Investig Drugs (2001) 2(12):1751-1756.
84. Costello K, Sipe JC: Cladribine tablets' potential in multiple: sclerosis treatment. J Neurosci Nurs (2008) 40(5):275-280.
85. Sipe JC: Cladribine for multiple sclerosis: Review and current status. Expert Rev Neurother (2005) 5(6):721-727.
86. Warren KG, Catz I, Ferenczi LZ, Krantz MJ: Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA class II-defined cohort of patients with progressive multiple sclerosis: Results of a 24-month double-blind placebo- controlled clinical trial and 5 years of follow-up treatment. Eur J Neurol (2006) 13(8):887-895.
87. Turley DM, Miller SD: Prospects for antigen-specific tolerance based therapies for the treatment of multiple sclerosis. In: Results and Problems in Cell Differentiation. Richter D, Tiedge H (Eds), Springer Berlin/Heidelberg, Berlin, Germany (2009):doi:10.1007/400-2008-13.
88. Dawson DA, Wadsworth G, Palmer AM: A comparative assessment of the efficacy and side-effect liability of neuroprotective compounds in experimental stroke. Brain Res (2001) 892(2):344-350.
89. Ginsberg MD: Neuroprotection for ischemic stroke: Past, present and future. Neuropharmacology (2008) 55(3):363-389.
90. Lassmann H: Multiple sclerosis: Is there neurodegeneration independent from inflammation? J Neurol Sci (2007) 259(1-2):3-6.
91. Garthwaite G, Goodwin DA, Batchelor AM, Leeming K, Garthwaite J: Nitric oxide toxicity in CNS white matter: An in vitro study using rat optic nerve. Neuroscience (2002) 109(1):145-155.
92. Bechtold DA, Miller SJ, Dawson AC, Sun Y, Kapoor R, Berry D, Smith KJ: Axonal protection achieved in a model of multiple sclerosis using lamotrigine. J Neurol (2006) 253(12):1542-1551.
93. Black JA, Waxman SG: Phenytoin protects central axons in experimental autoimmune encephalomyelitis. J Neurol Sci (2008) 274(1-2):57-63.
94. Kapoor R: Sodium channel blockers and neuroprotection in multiple sclerosis using lamotrigine. J Neurol Sci (2008) 274(1-2):54- 56.
95. Baker D, Pryce G: The endocannabinoid system and multiple sclerosis. Curr Pharm Des (2008) 14(23):2326-2336.
96. Pertwee RG: Cannabinoids and multiple sclerosis. Mol Neurobiol (2007) 36(1):45-59.
97. Teare L, Zajicek J: The use of cannabinoids in multiple sclerosis. Expert Opin Investig Drugs (2005) 14(7):859-869.
98. CUPID: Welcome to the CUPID study. Peninsula Medical School, Plymouth, UK (2009). www.pms.ac.uk/cnrg/cupid.php.
99. Korenke AR, Rivey MP, Allington DR: Sustained-release fampridine for symptomatic treatment of multiple sclerosis. Ann Pharmacother (2008) 42(10):1458-1465.
100. The disease-modifying drugs: Newly diagnosed. National Multiple Sclerosis Society, New York, NY, USA (2008). www. nationalmssociety.org/ download.aspx?id=45.
101. Pipex Pharmaceuticals' oral TRIMESTA initiates enrollment of phase II/III clinical trial for multiple sclerosis. Genetic Engineering News & Biotechnology News, New Rochelle, NY, USA (2007). www.genengnews.com/news/ bnitem. aspx?name=18838956&taxid=35
102. ATL1102 - For multiple sclerosis. Antisense Therapeutics Ltd, Toorak, Victoria, Australia (2008). www.antisense.com.au/-116.asp
103. Garren H, Robinson WH, Krasulová E, Havrdová E, Nadj C, Selmaj K, Losy J, Nadj I, Radue EW, Kidd BA, Gianettoni J et al: Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Ann Neurol (2008) 63(5):611-620.
104. Hutas G: Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies. Curr Opin Investig Drugs (2008) 9(11):1206-1215.
105. Castillo J, Milani C, Mendez-Allwood D: Ofatumumab, a second- generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders. Expert Opin Investig Drugs (2009) 18(4):491-500.
106. Millennium Pharmaceuticals Inc: Form 10-K 2007 - Millennium. Company Publication (2008): 29 February.
107. Solovax. Adeona Pharmaceuticals Inc, Ann Arbor, MI, USA (2008). www.adeonapharma.com/businessdevelopment.php?pageID=38.
108. Barnes MP: Sativex: Clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opin Pharmacother (2006) 7(5):607-615.
109. MultiCell Technologies Inc: MultiCell Technologies in-licenses phase IIb/III drug for the treatment of fatigue in multiple sclerosis from Amarin Corporation. Press Release (2006): 04 January.
110. Amarin Corp plc: Amarin licenses phase IIb/III drug for the treatment of fatigue in multiple sclerosis to Multicell Inc. Press Release (2006): 03 January.
111. Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN: Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: A two centre phase 2 study. J Neurol Neurosurg Psychiatry (2002) 72(2):179-183.
112. Lange R, Volkmer M, Heesen C, Liepert J: Modafanil effects multiple sclerosis patients with fatigue. J Neurol (2009):doi:10.1007/s00415- 009-0152-7.